<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02620007</url>
  </required_header>
  <id_info>
    <org_study_id>P140503</org_study_id>
    <nct_id>NCT02620007</nct_id>
  </id_info>
  <brief_title>Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease</brief_title>
  <acronym>TEOREM</acronym>
  <official_title>Multicenter Double Blind Randomized Clinical Trial Assessing the Benefit of Adherent Invasive E. Coli Eradication in Adult Ileal and Ileo-colonic Crohn Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to assess whether a 12-week treatment with
      Ciprofloxacin and Rifaximin is superior to placebo to obtain endoscopic remission in
      adherent-invasive E. coli (AIEC)-colonized patients with ileal Crohn disease (CD), with or
      without involvement of the caecum or the right colon.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with Endoscopic Endoscopic Index of Severity (CDEISm)&lt; 6 and a decrease in CDEISm ≥ 3</measure>
    <time_frame>week 12</time_frame>
    <description>(assessed within each site quotation), defined by the modified Crohn's Disease Endoscopic Index of Severity (CDEISm)&lt; 6 and a decrease in CDEISm ≥ 3, as compared to baseline values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean variation of CDEISm</measure>
    <time_frame>week 12</time_frame>
    <description>assessed by centralized, anonymous and blinded reading of ileocolonoscopies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete endoscopic remission</measure>
    <time_frame>week 12</time_frame>
    <description>assessed by centralized, anonymous and blinded reading of ileocolonoscopies, and defined by a CDEISm &lt;3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No ulceration</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>12 and 48 weeks</time_frame>
    <description>defined by Crohn's disease activity index (CDAI)&lt;150 without steroids, anti-Tumor Necrosis Factor (TNF), and surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota composition</measure>
    <time_frame>weeks 12 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lpf positive AIEC bacteria in the stools</measure>
    <time_frame>weeks 12 and 48</time_frame>
    <description>Detection (by PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological remission</measure>
    <time_frame>weeks 4, 8, 12, 24, 36 and 48</time_frame>
    <description>defined by haemoglobin level ≥13g/dL and C-Reactive Protein (CRP) serum level ≤5 mg/L and fecal calprotectin &lt;300 mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>week 12</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Adherent-invasive E. Coli</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral Ciprofloxacin 500 mg bid and oral Rifaximin 800 mg bid for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a placebo of Ciprofloxacin bid and a placebo of Rifaximin bid for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>oral Rifaximin 800 mg bid for 12 weeks</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin Placebo</intervention_name>
    <description>a placebo of Ciprofloxacin bid for 12 weeks</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin Placebo</intervention_name>
    <description>a placebo of Rifaximin bid for 12 weeks</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CD of the ileum, with or without involvement of the caecum or the right colon

          -  Colonoscopy showing active lesions defined by a CDEISm score &gt;6

          -  Informed consent to participate in this study

          -  Prescription of steroid treatments : Budesonide, Prednisone (or Prednisolone)
             independently from entry in study

          -  Patients who respond to budesonide (initial dose 9 mg/d) or prednisone or prednisolone
             (initial dose 40 mg/d), defined as a 70 points decrease in CDAI between the
             pre-inclusion and the inclusion visit,

          -  Patients colonized with AIEC on initial ileal biopsies.

        Exclusion Criteria:

          -  Ileal stenosis that cannot be crossed by the endoscope,

          -  Infliximab treatment received less than 8 weeks before inclusion in this study,

          -  Adalimumab treatment received less than 4 weeks before inclusion in this study,

          -  Vedolizumab treatment received less than 8 weeks before inclusion in the study,

          -  Hypersensitivity to Ciprofloxacin, to other quinolones, or to any of the excipients
             (cellulose microcrystalline, crospovidone, maize starch, magnesium stearate, silica
             colloidal anhydrous,, hypromellose titanium dioxide E171, macrogol 4000,),

          -  Tizanidine, Probenecid, Theophylline, Xanthine derivatives, Phenytoin, oral
             anticoagulants, and Ropinirole treatment,

          -  Hypersensitivity to Rifaximin, or to any excipients (sodium starch glycolate type A,
             glycerol distearate, colloidal anhydrous silica, talc, microcrystalline cellulose,
             hypromellose, titanium dioxide, disodium edentate, propylene glycol, red iron oxide
             E172),

          -  Previous extensive ileal surgery (≥ 1 meter as measured on the pathology and/or
             surgical report),

          -  Short bowel syndrome,

          -  Need for an intestinal resection for fistula, abscess or intestinal obstruction,

          -  Renal failure (creatinine clearance&lt;30 mL/min/1.73m2),

          -  Liver failure (V factor&lt;50%),

          -  Past history of epilepsy,

          -  No health insurance,

          -  Pregnant or lactating women,

          -  Refusal to have a double effective contraception,

          -  Patients already included in a biomedical research other than an observational study
             (e.g: registry, cohort).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Barnich, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Intestinal bacterial pathogenesis laboratory</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franck Carbonnel, MDPhD</last_name>
    <phone>33 1 45 32 37 22</phone>
    <email>fcarbonnel7@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kremlin-Bicetre hospital</name>
      <address>
        <city>Kremlin-Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck Carbonnel, MPhD</last_name>
      <phone>: +33 145213722</phone>
      <email>fcarbonnel7@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterology department</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Carbonnel, MDPhD</last_name>
      <email>fcarbonnel7@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult</keyword>
  <keyword>AIEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

